All In Biotech

Drug Trial Radar · NCT07493330

Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

Genotype-guided Targeted Agents in Combination With EZH2 Inhibitor, Zeprumetostat for Primary Refractory Peripheral T-cell Lymphoma (PTCL), a Prospective, Open-label, Multi-center Study

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

86

Planned (sponsor's estimate)

Start

Mar 23, 2026

Primary completion

Dec 12, 2029

Study completion Dec 12, 2030

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).

Conditions

  • PTCL
  • Refractory

Interventions

  • Zeprumetostat+AzacitadineDrug

    Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Azacitadine :100mg D1-D7, subcutaneous injection, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Azacitidine 100 mg D1-D5, subcutaneous injection for total 3 cycles.

  • Zeprumetostat+DecitabineDrug

    Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Decitabine 10mg/m2 D1-D5, intravenous infusion, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Decitabine 10mg/m2 D1-D3 for total 3 cycles.

  • Zeprumetostat+ChidamideDrug

    Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Chidamide 30 mg biw orally, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Chidamide 20 mg biw for total 3 cycles.

  • Zeprumetostat+GolidocitinibDrug

    Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Golidocitinib 150 mg qd orally, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Golidocitinib 150 mg qod for total 3 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of DLT events (Phase Ib)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Overall response rate (Phase Ⅱ)Time frame: At the end of Cycle 3 (each cycle is 28 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.